This is an aggregated industry headline. Read the full story at AJMC →
Tags
pipelineformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
PipelineFiercePharma ↗
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
PipelineFiercePharma ↗
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
PipelineFiercePharma ↗
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …